AC Immune SA (NASDAQ:ACIU) Shares Purchased by Redmile Group LLC

Redmile Group LLC increased its holdings in AC Immune SA (NASDAQ:ACIU) by 0.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,007,031 shares of the company’s stock after purchasing an additional 7,031 shares during the quarter. Redmile Group LLC owned 2.03% of AC Immune worth $5,941,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. BVF Inc. IL raised its stake in shares of AC Immune by 96.2% during the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock worth $72,856,000 after buying an additional 7,142,857 shares during the period. Avidity Partners Management LP grew its stake in AC Immune by 50.5% during the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company’s stock valued at $22,345,000 after acquiring an additional 1,499,280 shares in the last quarter. Platinum Investment Management Ltd. raised its stake in AC Immune by 14.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock worth $7,578,000 after purchasing an additional 193,123 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of AC Immune by 96.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock valued at $56,000 after purchasing an additional 9,334 shares during the last quarter. Finally, Nixon Peabody Trust Co. purchased a new position in shares of AC Immune during the 4th quarter worth approximately $64,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

Analysts Set New Price Targets

ACIU has been the topic of a number of analyst reports. StockNews.com upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. BTIG Research assumed coverage on AC Immune in a report on Friday, May 31st. They issued a “buy” rating and a $8.00 price target for the company.

AC Immune Trading Up 3.6 %

Shares of AC Immune stock traded up $0.14 during trading hours on Monday, reaching $4.05. The stock had a trading volume of 207,274 shares, compared to its average volume of 472,454. AC Immune SA has a 1 year low of $2.20 and a 1 year high of $5.14. The firm has a 50 day simple moving average of $3.94 and a two-hundred day simple moving average of $3.43. The firm has a market capitalization of $400.55 million, a price-to-earnings ratio of -5.78 and a beta of 1.27.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). Sell-side analysts forecast that AC Immune SA will post -0.2 EPS for the current year.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.